24 completed, 2 active not recruiting, 2 terminated, 1 recruiting. 30 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 30 | Completed 24, Active not recruiting 2, Terminated 2, Recruiting 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow mepolizumab: new trials by email Literature Review of mepolizumab trials Research Report on mepolizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA） SHR-1703, Mepolizumab Injection - Eosinophilic Granulomatosis With Polyangiitis | Phase 2 / Phase 3 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 166 | 2023-11-16 | 2025-12-04 |
| Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) Mepolizumab - Hypereosinophilic Syndrome | Phase 3 | Completed | GlaxoSmithKline | 16 | 2022-07-14 | 2026-07-06 |
| Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Depemokimab, Mepolizumab, Placebo matching mepolizumab - Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Active not recruiting | GlaxoSmithKline | 163 | 2022-07-14 | 2026-07-08 |
| Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) Mepolizumab, cyclophosphamide/azathioprine, Placebo - Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 102 | 2022-05-30 | 2026-10-01 |
| A Pilot Study of the Use of 129Xe and 1H MRI to Measure the Modulation of Eosinophil-Related Inflammation by Mepolizumab In COPD Mepolizumab 100 MG - COPD | Phase 3 | Completed | Sheffield Teaching Hospitals NHS Foundation Trust | 31 | 2022-05-08 | 2026-05-07 |
| Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS) Mepolizumab, Placebo, Standard of care - Nasal Polyps | Phase 3 | Completed | GlaxoSmithKline | 169 | 2021-02-08 | 2026-07-22 |
| A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype GSK3511294 (Depemokimab), Mepolizumab, Benralizumab - Asthma | Phase 3 | Completed | GlaxoSmithKline | 1717 | 2021-01-26 | 2026-05-18 |
| Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial Mepolizumab, Placebo - COPD, Eosinophilia | Phase 2 / Phase 3 | Completed | University of Leicester | 238 | 2020-09-07 | 2026-04-24 |
| Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level Mepolizumab, Placebo - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | GlaxoSmithKline | 806 | 2019-10-30 | 2026-08-21 |
| Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. Benralizumab, Mepolizumab, Placebo to Mepolizumab - Eosinophilic Granulomatous Vasculitis | Phase 3 | Active not recruiting | AstraZeneca | 140 | 2019-10-29 | 2026-08-12 |
| A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 Mepolizumab - Hypereosinophilic Syndrome | Phase 3 | Completed | GlaxoSmithKline | 102 | 2017-11-13 | 2020-06-23 |
| Effect of Mepolizumab in Severe Bilateral Nasal Polyps Mepolizumab, Placebo, Mometasone furoate - Nasal Polyps | Phase 3 | Completed | GlaxoSmithKline | 414 | 2017-05-25 | 2026-07-22 |
| Study of Mepolizumab Autoinjector in Asthmatics Mepolizumab - Asthma | Phase 3 | Completed | GlaxoSmithKline | 159 | 2017-05-04 | 2023-06-28 |
| Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone) - Hypereosinophilic Syndrome | Phase 3 | Completed | GlaxoSmithKline | 108 | 2017-03-07 | 2020-02-21 |
| Study of Mepolizumab Safety Syringe in Asthmatics Mepolizumab - Asthma | Phase 3 | Completed | GlaxoSmithKline | 56 | 2017-02-01 | 2019-07-23 |
| Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients Mepolizumab 100mg, Placebo - Asthma | Phase 3 | Completed | GlaxoSmithKline | 306 | 2016-01-07 | 2020-02-05 |
| Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study Mepolizumab, Placebo - Asthma | Phase 3 | Terminated | Johannes Gutenberg University Mainz | 29 | 2015-11-17 | 2017-07-13 |
| Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Mepolizumab, Prednisolone - Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Completed | GlaxoSmithKline | 100 | 2015-04-14 | 2024-03-12 |
| Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Mepolizumab, Placebo, SOC - Asthma | Phase 3 | Completed | GlaxoSmithKline | 556 | 2014-12-11 | 2018-08-06 |
| A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Mepolizumab, SOC - Asthma | Phase 3 | Completed | GlaxoSmithKline | 339 | 2014-05-29 | 2019-12-03 |
Showing 20 of 30. Sign in to see all of them.
Asthma (11) · Churg-Strauss Syndrome (6) · Pulmonary Disease, Chronic Obstructive (6) · Pulmonary Eosinophilia (6) · Hypereosinophilic Syndrome (5) · Eosinophilia (4) · Nasal Polyps (2) · Bronchitis (1) · Infections (1) · Inflammation (1) · Systemic Vasculitis (1) · Virus Diseases (1)
GlaxoSmithKline (22) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Johannes Gutenberg University Mainz (1) · McMaster University (1) · Sheffield Teaching Hospitals NHS Foundation Trust (1) · University of Leicester (1)
United States (21) · Canada (19) · Germany (19) · France (18) · United Kingdom (17) · Italy (13) · Australia (12) · Belgium (12) · Netherlands (12) · Argentina (11) · Spain (11) · Japan (10) · Poland (10) · Russia (10) · South Korea (7)
Christopher Brightling (1) · Elisabeth H Bel, MD, PhD (1) · Michael Wechsler, MD (1) · Neil Greening (1) · Parameswaran Nair, MD,PhD,FRCP (1) · Peter J Sterk, PhD (1) · Rod Lawson (1) · Stephanie Korn, MD (1)
PMID 30954640, PMID 28893134, PMID 30370691, PMID 31047111, PMID 31295674, PMID 31447130, PMID 31507641, PMID 34098955, PMID 34163157, PMID 34389506, PMID 18344568, PMID 20810155, PMID 25199060, PMID 27087007, PMID 27553751, PMID 28298405, PMID 28395936, PMID 28514601, PMID 29949045, PMID 30406948, PMID 31251094, PMID 32956756, PMID 33164993, PMID 33710614, PMID 34158028, PMID 34172470, PMID 35493455, PMID 35568330, PMID 35822924, PMID 35972211, PMID 36091012, PMID 36662344, PMID 37064032, PMID 37586475, PMID 38393328, PMID 39393433, PMID 40008472, PMID 40305842, PMID 40977418
2016 (3), 2014 (2), 2015 (2), 2023 (2), 2017 (1), 2019 (1)